Evidence map›Paper›PMID 39364227›Full record

ArticleImmunoTargets and therapy2024

EPS T14 from

Gaetana Pezzino, Alessia Calabrò, Fabiana Drommi, Stefania Campana, Riccardo Cavaliere, Irene Bonaccorsi, Paolo Carrega, Vincenzo Zammuto, Maria Giovanna Rizzo, Concetta Gugliandolo and 2 more

Abstract read
In one paragraph

Article in ImmunoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gaetana PezzinoLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Alessia CalabròLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Fabiana DrommiLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Stefania CampanaLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Riccardo CavaliereLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Irene BonaccorsiLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Paolo CarregaLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Vincenzo ZammutoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Maria Giovanna RizzoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Concetta GugliandoloDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Guido FerlazzoDepartment of Experimental Medicine (DIMES), University of Genoa, Genova, Italy.
Claudia De PasqualeLaboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.ORCID 0009-0008-5250-1970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory viral infections are a leading cause of severe diseases and mortality; therefore, novel treatments effective for their prevention are highly requested. Here, we identified a broad-spectrum antiviral activity of a natural exopolysaccharide, EPS T14, purified from a marine thermotolerant strain of Methods: The effects on human normal nasal epithelial cells (HNEpCs) following treatment with EPS T14 was evaluated at different time points and with increasing concentration of compound. To assess the antiviral properties, viability of HNEpCs treated with EPS T14 was analysed following infection with different respiratory viruses. Results: Neither toxicity nor pro-inflammatory properties were observed in vitro on HNEpCs treated with EPS T14 up to high concentrations, thus ensuring its safety. Cell culture-based assays revealed that treatment of HNEpCs with EPS T14 (used at 400ug/mL) results in efficient prevention of cell infection by different respiratory viruses through physically hindering the entry of the viruses via cell surface receptors. Interestingly, in addition to this prophylactic antiviral activity, EPS T14 also shows a long-lasting efficacy by inhibiting viral spread in the cell culture. Finally, combination of EPS T14 with a hypertonic saline solution shows a synergistic antiviral activity. Conclusion: EPS T14 can exert both prophylactic and therapeutic antiviral activity by blocking viral attachment to cellular receptors and could therefore represent a promising antiviral agent for preventing infections by different respiratory viruses.

Indexed as

EPSsexopolysaccharidesinfection prophylaxisnasal epitheliumrespiratory virusviral infection

Identifiers

PMID39364227
PMCPMC11446858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.